Stephen C Mathai1, Tomeka Suber2, Rubina M Khair1, Todd M Kolb1, Rachel L Damico1, Paul M Hassoun1. 1. 1 Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland; and. 2. 2 Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Abstract
RATIONALE: Pulmonary arterial hypertension is a progressive disease with high morbidity and mortality despite advances in medical therapy. The relationship between patient-related outcomes, such as health-related quality of life (HRQOL), and survival is not well described. OBJECTIVE: To assess the relationship between HRQOL and outcomes in patients with pulmonary arterial hypertension. METHODS: Consecutive patients with right heart catheterization-proven pulmonary arterial hypertension who completed the Medical Outcomes Survey Short Form-36 survey (SF-36) were included. Demographic, clinical, physiological, and hemodynamic data were collected at baseline. Survival was assessed from the time of diagnosis of pulmonary arterial hypertension. Cox proportional hazard models were constructed to assess the relationship between HRQOL and transplant-free survival. MEASUREMENTS AND MAIN RESULTS: Eighty-seven patients with pulmonary arterial hypertension were enrolled and followed prospectively for a median of 3.8 years. At baseline, HRQOL was significantly worse than U.S. normal values for six of eight domains of the SF-36. Several domains demonstrated moderate correlation (r value ≥ 0.40) with 6-minute-walk distance and World Health Organization functional class; there were no significant associations with hemodynamics. In univariable Cox proportional hazard models, six of eight domains and both summary scores were significantly associated with survival. In multivariable models, adjusted for age, disease type, and cardiac function, these relationships largely persisted. CONCLUSIONS: In this cohort of patients with pulmonary arterial hypertension, HRQOL, as assessed by the SF-36, was strongly associated with transplant-free survival. These relationships persisted when controlling for potential confounders such as disease type and disease severity. These findings suggest that HRQOL may be an important predictor of outcomes in pulmonary arterial hypertension and therefore a target for future therapeutic interventions.
RATIONALE: Pulmonary arterial hypertension is a progressive disease with high morbidity and mortality despite advances in medical therapy. The relationship between patient-related outcomes, such as health-related quality of life (HRQOL), and survival is not well described. OBJECTIVE: To assess the relationship between HRQOL and outcomes in patients with pulmonary arterial hypertension. METHODS: Consecutive patients with right heart catheterization-proven pulmonary arterial hypertension who completed the Medical Outcomes Survey Short Form-36 survey (SF-36) were included. Demographic, clinical, physiological, and hemodynamic data were collected at baseline. Survival was assessed from the time of diagnosis of pulmonary arterial hypertension. Cox proportional hazard models were constructed to assess the relationship between HRQOL and transplant-free survival. MEASUREMENTS AND MAIN RESULTS: Eighty-seven patients with pulmonary arterial hypertension were enrolled and followed prospectively for a median of 3.8 years. At baseline, HRQOL was significantly worse than U.S. normal values for six of eight domains of the SF-36. Several domains demonstrated moderate correlation (r value ≥ 0.40) with 6-minute-walk distance and World Health Organization functional class; there were no significant associations with hemodynamics. In univariable Cox proportional hazard models, six of eight domains and both summary scores were significantly associated with survival. In multivariable models, adjusted for age, disease type, and cardiac function, these relationships largely persisted. CONCLUSIONS: In this cohort of patients with pulmonary arterial hypertension, HRQOL, as assessed by the SF-36, was strongly associated with transplant-free survival. These relationships persisted when controlling for potential confounders such as disease type and disease severity. These findings suggest that HRQOL may be an important predictor of outcomes in pulmonary arterial hypertension and therefore a target for future therapeutic interventions.
Entities:
Keywords:
outcomes; pulmonary hypertension; quality of life
Authors: Lorinda Chung; Juliana Liu; Lori Parsons; Paul M Hassoun; Michael McGoon; David B Badesch; Dave P Miller; Mark R Nicolls; Roham T Zamanian Journal: Chest Date: 2010-05-27 Impact factor: 9.410
Authors: Daniel Aletaha; Tuhina Neogi; Alan J Silman; Julia Funovits; David T Felson; Clifton O Bingham; Neal S Birnbaum; Gerd R Burmester; Vivian P Bykerk; Marc D Cohen; Bernard Combe; Karen H Costenbader; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Johanna M W Hazes; Kathryn Hobbs; Tom W J Huizinga; Arthur Kavanaugh; Jonathan Kay; Tore K Kvien; Timothy Laing; Philip Mease; Henri A Ménard; Larry W Moreland; Raymond L Naden; Theodore Pincus; Josef S Smolen; Ewa Stanislawska-Biernat; Deborah Symmons; Paul P Tak; Katherine S Upchurch; Jirí Vencovský; Frederick Wolfe; Gillian Hawker Journal: Arthritis Rheum Date: 2010-09
Authors: Darren B Taichman; Michael D McGoon; Michael O Harhay; Chris Archer-Chicko; Jeffrey S Sager; Meena Murugappan; Murali M Chakinali; Harold I Palevsky; Robert Gallop Journal: Mayo Clin Proc Date: 2009-07 Impact factor: 7.616
Authors: Maria Clemencia Zuluaga; Pilar Guallar-Castillón; Esther López-García; José R Banegas; Manuel Conde-Herrera; Maite Olcoz-Chiva; Carlos Rodríguez-Pascual; Fernando Rodriguez-Artalejo Journal: Eur J Heart Fail Date: 2010-09-22 Impact factor: 15.534
Authors: Raymond L Benza; Dave P Miller; Mardi Gomberg-Maitland; Robert P Frantz; Aimee J Foreman; Christopher S Coffey; Adaani Frost; Robyn J Barst; David B Badesch; C Gregory Elliott; Theodore G Liou; Michael D McGoon Journal: Circulation Date: 2010-06-28 Impact factor: 29.690
Authors: Claire Gilbert; Martin C J Brown; Joseph C Cappelleri; Martin Carlsson; Stephen P McKenna Journal: Chest Date: 2008-09-23 Impact factor: 9.410
Authors: Kathryn E Flynn; Ileana L Piña; David J Whellan; Li Lin; James A Blumenthal; Stephen J Ellis; Lawrence J Fine; Jonathan G Howlett; Steven J Keteyian; Dalane W Kitzman; William E Kraus; Nancy Houston Miller; Kevin A Schulman; John A Spertus; Christopher M O'Connor; Kevin P Weinfurt Journal: JAMA Date: 2009-04-08 Impact factor: 56.272
Authors: Thomas M Cascino; Vallerie V McLaughlin; Caroline R Richardson; Nilofar Behbahani-Nejad; Victor M Moles; Scott H Visovatti; Elizabeth A Jackson Journal: Eur Respir J Date: 2019-06-20 Impact factor: 16.671
Authors: Annelieke C M J van Riel; Alexander R Opotowsky; Mário Santos; Jose M Rivero; Andy Dhimitri; Barbara J M Mulder; Berto J Bouma; Michael J Landzberg; Aaron B Waxman; David M Systrom; Amil M Shah Journal: Circ Cardiovasc Imaging Date: 2017-04 Impact factor: 7.792
Authors: Hilary M DuBrock; Yogesh N Reddy; Louise A Durst; Darrell R Schroeder; Grace Park; Hector R Cajigas; Garvan C Kane; Sudhir S Kushwaha; Robert B McCully; Joseph G Murphy; Vidhu Anand; Michael J Krowka; Robert P Frantz Journal: Pulm Circ Date: 2022-10-01 Impact factor: 2.886
Authors: Anna R Hemnes; Luke G Silverman-Lloyd; Shi Huang; Grant MacKinnon; Jeffrey Annis; Carolyn S Whitmore; Ravinder Mallugari; Rashundra N Oggs; Rezzan Hekmat; Rongzi Shan; Pauline P Huynh; Chang Yu; Seth S Martin; Michael J Blaha; Evan L Brittain Journal: Chest Date: 2021-04-17 Impact factor: 10.262
Authors: Thomas P Walsh; Grayson L Baird; Michael K Atalay; Saurabh Agarwal; Daniel Arcuri; James R Klinger; Christopher J Mullin; Heather Morreo; Brynn Normandin; Sruti Shiva; Mary Whittenhall; Corey E Ventetuolo Journal: Pulm Circ Date: 2021-05-21 Impact factor: 3.017